Axonics® to Participate in the Piper Sandler Healthcare Conference
November 18 2022 - 6:00AM
Business Wire
Axonics, Inc. (Nasdaq: AXNX), a global medical technology
company that is developing and commercializing novel products for
the treatment of bladder and bowel dysfunction, will participate in
the Piper Sandler Healthcare Conference on December 1, 2022.
Axonics is scheduled to present at 11:00 a.m. Eastern Time. A
live webcast and archived replay of the presentation will be
accessible on the Axonics investor relations website.
About Axonics
Axonics is a global medical technology company that is
developing and commercializing novel products for adults with
bladder and bowel dysfunction. Axonics recently ranked No. 1 on the
2022 Financial Times ranking of the 500 fastest growing companies
in the Americas and No. 4 on the 2022 Deloitte Technology Fast 500™
following its No. 1 ranking in 2021.
Axonics sacral neuromodulation (SNM) systems provide patients
suffering from overactive bladder and/or fecal incontinence with
long-lived, easy to use, safe, clinically effective therapy. In
addition, the company’s best-in-class urethral bulking hydrogel,
Bulkamid®, provides safe and durable symptom relief to women with
stress urinary incontinence (SUI). Overactive bladder affects an
estimated 87 million adults in the U.S. and Europe, with an
additional 40 million adults estimated to suffer from fecal
incontinence. SUI affects an estimated 29 million women in the U.S.
alone. Axonics’ clinically proven products are offered at hundreds
of medical centers across the U.S. and abroad. Reimbursement
coverage is well established in the U.S. and is a covered service
in most European countries. For more information, visit
www.axonics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221118005032/en/
Axonics Neil Bhalodkar Investor Relations 949-336-5293
ir@axonics.com
Axonics (NASDAQ:AXNX)
Historical Stock Chart
From Apr 2024 to May 2024
Axonics (NASDAQ:AXNX)
Historical Stock Chart
From May 2023 to May 2024